{
  "trial_id": "NCT00001575",
  "overall_assessment": "likely_ineligible",
  "inclusion": [
    {
      "criterion": "histologically confirmed diagnosis of Hodgkin's disease",
      "label": "met"
    },
    {
      "criterion": "more than 100 days post-transplant",
      "label": "met"
    },
    {
      "criterion": "at least 10% of malignant cells react with anti-Tac",
      "label": "met"
    },
    {
      "criterion": "Tac positivity in infiltrating T cells",
      "label": "met"
    },
    {
      "criterion": "Non-Hodgkin's Lymphoma (NHL)",
      "label": "met"
    },
    {
      "criterion": "Stage Disease: 1) Non-Hodgkin's Lymphoma (NHL)",
      "label": "met"
    },
    {
      "criterion": "Hodgkin's disease",
      "label": "met"
    },
    {
      "criterion": "Cutaneous T-cell Lymphoma (CTCL)",
      "label": "met"
    },
    {
      "criterion": "Peripheral T-cell Lymphoma (PTCL)",
      "label": "met"
    },
    {
      "criterion": "Other",
      "label": "met"
    },
    {
      "criterion": "Karnofsky performance status of at least 50",
      "label": "met"
    },
    {
      "criterion": "creatinine less than 2.0 mg/dl",
      "label": "met"
    }
  ],
  "exclusion": [
    {
      "criterion": "Female patients of child bearing potential will be tested for pregnancy",
      "label": "triggers"
    },
    {
      "criterion": "Patients who are human immunodeficiency virus (HIV) antibody positive",
      "label": "triggers"
    },
    {
      "criterion": "Patients with symptomatic disease that is due to malignant involvement of the central nervous system",
      "label": "triggers"
    },
    {
      "criterion": "Patients with active second primary cancer",
      "label": "triggers"
    },
    {
      "criterion": "Patients receiving chronic anticoagulant therapy",
      "label": "triggers"
    },
    {
      "criterion": "Patients requiring urgent chemotherapy or radiation therapy for management of their malignancy",
      "label": "triggers"
    }
  ],
  "notes": "Patient has a large pericardial effusion with Burkitt's lymphoma, but is not eligible due to exclusion criteria.",
  "_meta": {
    "topic_id": "4",
    "trial_id": "NCT00001575",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}